[1] Oviedo C, Maehara A, Mintz GS, et al. Intravascular ultrasound classification of plaque distribution in left main coronary artery bifurcations: where is the plaque really located? Circ Cardiovasc Interv 2010; 3: 105−112. doi: 10.1161/CIRCINTERVENTIONS.109.906016 [2] Park SJ, Lee CW, Hong MK, et al. Stent placement for ostial left anterior descending coronary artery stenosis: acute and long-term (2-year) results. Catheter Cardiovasc Interv 2000; 49: 267−271. doi: 10.1002/(SICI)1522-726X(200003)49:33.0.CO;2-H [3] Asakaura Y, Takagi S, Ishikawa S, et al. Favorable strategy for the ostial lesion of the left anterior descending coronary artery: influence on narrowing of circumflex coronary artery. Cathet Cardiovasc Diagn 1998; 43: 95−100. doi: 10.1002/(SICI)1097-0304(199801)43:13.0.CO;2-R [4] Rigatelli G, Zuin M, Baracca E, et al. Long-term clinical outcomes of isolated ostial left anterior descending disease treatment: ostial stenting versus left main cross-over stenting. Cardiovasc Revasc Med 2019; 20: 1058−1062. doi: 10.1016/j.carrev.2019.01.030 [5] Lu W, Zhu Y, Han Z, et al. Drug-coated balloon in combination with bare metal stent strategy for de novo coronary artery disease: a PRISMA-compliant meta-analysis of randomized clinical trials. Medicine (Baltimore) 2017; 96: e6397. doi: 10.1097/MD.0000000000006397 [6] Wang X, Lu W, Wang X, et al. Drug-coated balloon angioplasty: predicting outcomes based on different patterns of drug-eluting stent restenosis. Int J Cardiovasc Imaging 2020; 36: 171−178. doi: 10.1007/s10554-019-01681-y [7] Lu W, Zhu Y, Han Z, et al. Short-term outcomes from drug-coated balloon for coronary de novo lesions in large vessels. J Cardiol 2019; 73: 151−155. doi: 10.1016/j.jjcc.2018.07.008 [8] Jeger RV, Farah A, Ohlow MA, et al. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet 2020; 396: 1504−1510. doi: 10.1016/S0140-6736(20)32173-5 [9] Ali RM, Degenhardt R, Zambahari R, et al. Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus. EuroIntervention 2011; 7: K83−K92. doi: 10.4244/EIJV7SKA15 [10] Pan L, Lu W, Han Z, et al. Clinical outcomes of drug-coated balloon in coronary lesions: a real-world, all-comers study. Clin Res Cardiol 2022; 111: 732−741. doi: 10.1007/s00392-021-01895-y [11] López Mínguez JR, Nogales Asensio JM, Doncel Vecino LJ, et al. A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results. EuroIntervention 2014; 10: 50−57. doi: 10.4244/EIJV10I1A10 [12] Worthley S, Hendriks R, Worthley M, et al. Paclitaxel-eluting balloon and everolimus-eluting stent for provisional stenting of coronary bifurcations: 12-month results of the multicenter BIOLUX-I study. Cardiovasc Revasc Med 2015; 16: 413−417. doi: 10.1016/j.carrev.2015.07.009 [13]

Lu WJ, Pan L, Han ZY, et al. Stentless at ostium: a novel approach for treating ostial left anterior descending or left circumflex coronary artery lesions with drug-coated balloons. Am J Transl Res 2022; 14: 6256−6267.

[14] Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39: 213−260. doi: 10.1093/eurheartj/ehx419 [15] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87−165. doi: 10.1093/eurheartj/ehy394 [16] Burzotta F, Lassen JF, Banning AP, et al. Percutaneous coronary intervention in left main coronary artery disease: the 13th consensus document from the European Bifurcation Club. EuroIntervention 2018; 14: 112−120. doi: 10.4244/EIJ-D-18-00357 [17] Huber MS, Mooney JF, Madison J, et al. Use of a morphologic classification to predict clinical outcome after dissection from coronary angioplasty. Am J Cardiol 1991; 68: 467−471. doi: 10.1016/0002-9149(91)90780-O [18] Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol 2018; 72: 2231−2264. doi: 10.1016/j.jacc.2018.08.1038 [19] Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020−1029. doi: 10.1056/NEJMoa067731 [20] Collet C, Onuma Y, Cavalcante R, et al. Quantitative angiography methods for bifurcation lesions: a consensus statement update from the European Bifurcation Club. EuroIntervention 2017; 13: 115−123. doi: 10.4244/EIJ-D-16-00932 [21] Burzotta F, Lassen JF, Lefèvre T, et al. Percutaneous coronary intervention for bifurcation coronary lesions: the 15th consensus document from the European Bifurcation Club. EuroIntervention 2021; 16: 1307−1317. doi: 10.4244/EIJ-D-20-00169 [22] Burzotta F, Lassen JF, Louvard Y, et al. European Bifurcation Club white paper on stenting techniques for patients with bifurcated coronary artery lesions. Catheter Cardiovasc Interv 2020; 96: 1067−1079. doi: 10.1002/ccd.29071 [23] Vaquerizo B, Fernández-Nofreiras E, Oategui I, et al. Second-generation drug-eluting balloon for ostial side branch lesions (001-bifurcations): mid-term clinical and angiographic results. J Interv Cardiol 2016; 29: 285−292. doi: 10.1111/joic.12292 [24] Tanaka A, Latib A, Jabbour RJ, et al. Impact of angiographic result after predilatation on outcome after drug-coated balloon treatment of in-stent coronary restenosis. Am J Cardiol 2016; 118: 1460−1465. doi: 10.1016/j.amjcard.2016.08.006 [25] Ielasi A, Buono A, Pellicano M, et al. A hybrid approach evaluating a drug-coated balloon in combination with a new-generation drug-eluting stent in the treatment of de novo diffuse coronary artery disease: the HYPER Pilot Study. Cardiovasc Revasc Med 2021; 28: 14−19. doi: 10.1016/j.carrev.2020.07.036 [26] Cortese B, Silva Orrego P, Agostoni P, et al. Effect of drug-coated balloons in native coronary artery disease left with a dissection. JACC Cardiovasc Interv 2015; 8: 2003−2009. doi: 10.1016/j.jcin.2015.08.029 [27] Mitomo S, Jabbour RJ, Mangieri A, et al. Mid-term clinical outcomes after bailout drug-eluting stenting for suboptimal drug-coated balloon results: insights from a Milan registry. Int J Cardiol 2018; 263: 17−23. doi: 10.1016/j.ijcard.2018.04.050